Lion Point Capital, LP
CIK 0001643354 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$20.9M
2026 Q2
Positions
35
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
55.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
CUE
CUE BIOPHARMA INC
8.0%
PRAX
PRAXIS PRECISION MEDICINES I
7.1%
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
6.3%
FENC
FENNEC PHARMACEUTICALS INC
5.8%
RPRX
ROYALTY PHARMA PLC
5.7%
CMPS
COMPASS PATHWAYS PLC
5.4%
MIST
MILESTONE PHARMACEUTICALS IN
5.3%
BNTC
BENITEC BIOPHARMA INC
4.0%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.